Olr168 inhibitors represent a class of chemical compounds that specifically target and modulate the activity of the Olr168 protein, which belongs to the olfactory receptor (OR) family. The olfactory receptors are a subset of G protein-coupled receptors (GPCRs) that are primarily known for their role in the detection of odor molecules, though their functions extend beyond olfaction, participating in various signaling pathways within different tissues. Olr168, like other olfactory receptors, is embedded within the cell membrane, where it can interact with various ligands. The binding of a specific inhibitor to Olr168 alters its conformation, subsequently blocking its ability to interact with its natural ligands. This interaction is highly specific, meaning that inhibitors are typically designed or selected based on their ability to fit the binding pocket of the Olr168 receptor, thereby preventing the receptor from initiating its usual signal transduction pathway.
The inhibition of Olr168 can have downstream effects on the signaling pathways that are normally activated by this receptor. Given that GPCRs like Olr168 are involved in a broad array of cellular processes, the inhibition of Olr168 may influence various intracellular mechanisms. This can include modulation of cyclic adenosine monophosphate (cAMP) levels, alteration of ion channel activity, or changes in gene expression, all of which are mediated by the inhibition of the GPCR's ability to activate its associated G proteins. The structural features of Olr168 inhibitors often include specific functional groups that enable high affinity and selective binding, such as aromatic rings, hydrophobic tails, or hydrogen-bond donors/acceptors that complement the receptor's active site. The precise nature of the interaction between Olr168 inhibitors and the receptor is a focus of chemical research, particularly in understanding how these inhibitors can be designed to achieve maximal specificity and efficiency in modulating receptor function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
MEK inhibitor, potentially affects the MAPK/ERK pathway which Olr168 might be involved in. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Proteasome inhibitor, might impact protein degradation processes relevant to Olr168. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
HDAC inhibitor, could alter chromatin structure and gene expression affecting Olr168. | ||||||
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
Bruton's tyrosine kinase inhibitor, may modulate cell signaling pathways relevant to Olr168. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
BCL-2 inhibitor, potentially influences apoptosis pathways linked to Olr168. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor, could affect cell cycle regulation pathways involving Olr168. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Multi-kinase inhibitor, might modulate various signaling pathways involving Olr168. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
RAF inhibitor, can influence multiple signaling pathways potentially impacting Olr168. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
EGFR inhibitor, potentially disrupts growth factor signaling pathways involving Olr168. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Src family kinase inhibitor, could modulate signaling pathways where Olr168 may be involved. | ||||||